Compare ZTS & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTS | RMD |
|---|---|---|
| Founded | 1952 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5B | 28.4B |
| IPO Year | 2012 | 1996 |
| Metric | ZTS | RMD |
|---|---|---|
| Price | $73.70 | $223.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $154.18 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 5.8M | 1.4M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.86% | 1.13% |
| EPS Growth | ★ 10.05 | 9.67 |
| EPS | 3.08 | ★ 10.43 |
| Revenue | ★ $9,467,000,000.00 | $2,957,013,000.00 |
| Revenue This Year | $5.63 | $10.60 |
| Revenue Next Year | $4.77 | $7.41 |
| P/E Ratio | ★ $24.62 | $29.10 |
| Revenue Growth | 2.28 | ★ 13.44 |
| 52 Week Low | $71.45 | $180.27 |
| 52 Week High | $160.48 | $293.81 |
| Indicator | ZTS | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 61.36 |
| Support Level | $73.42 | $218.39 |
| Resistance Level | $78.74 | $233.75 |
| Average True Range (ATR) | 3.08 | 7.14 |
| MACD | -0.06 | 1.23 |
| Stochastic Oscillator | 28.33 | 85.77 |
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.